Diosynth Biotechnology Announces Supply Agreement Extension with Pfizer for Production of a Recombinant Protein Drug

We are pleased to announce that Diosynth Biotechnology has signed a Supply Agreement extension with Pfizer for the continued manufacture of a recombinant protein drug substance.

Jacques van Kimmenaede, President of Diosynth Biotechnology noted that, "This extension with Pfizer demonstrates our commitment to the contract manufacturing business."  "We look forward to our continued relationship with Pfizer and all of our employees should be proud of our accomplishments and the important role which our company plays in the advancement of human health", Van Kimmenaede added.  This drug substance is one of the two licensed commercial products that Diosynth produces at its manufacturing facilities.

Diosynth Biotechnology offers contract cGMP manufacturing of biopharmaceuticals.  The company serves its customers by applying a full set of capabilities that range from cell line development to clinical and commercial manufacturing of both fermentation and cell culture derived drug substance.

Diosynth Biotechnology is a division of Organon that supplies contract manufacturing services for the global biotechnology industry. The company has an 80-year heritage in biologics manufacturing and is a global leader in technology-driven process development and cGMP manufacturing of recombinant proteins, monoclonal antibodies and peptides. We help our customers succeed by developing scalable and robust processes and by driving products efficiently, rapidly and cost-effectively from preclinical development to market supply. Diosynth Biotechnology serves pharmaceutical and biopharmaceutical customers globally and operates FDA-, Health Canada- and EMEA-inspected cGMP manufacturing facilities in Research Triangle Park, NC USA, and Oss, the Netherlands. Diosynth Biotechnology is part of Akzo Nobel's human healthcare business unit Organon. The Akzo Nobel Safe Harbor Statement (below) applies to this press release. For more information: http://www.diosynthbiotechnology.com/

Safe Harbor Statement*

This press release may contain statements which address such key issues as growth strategy, future financial results, market positions, product development, pharmaceutical products in the pipeline, and product approvals of Organon. Such statements should be carefully considered, and it should be understood that many factors could cause forecasted and actual results to differ from these statements. These factors include, but are not limited to, price fluctuations, currency fluctuations, progress of drug development, clinical testing and regulatory approval, developments in raw material and personnel costs, pensions, physical and environmental risks, legal issues, and legislative, fiscal, and other regulatory measures. Stated competitive positions are based on management estimates supported by information provided by specialized external agencies. For a more comprehensive discussion of the risk factors affecting our business please see our Annual Report on Form 20-F filed with the United States Securities and Exchange Commission, a copy of which can be found on the company's corporate website http://www.akzonobel.com/.

* Pursuant to the U.S. Private Securities Litigation Reform Act 1995.